OnKure Therapeutics
OKUR
38 hedge funds and large institutions have $171M invested in OnKure Therapeutics in 2021 Q2 according to their latest regulatory filings, with 38 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
7.53% more ownership
Funds ownership: 0% → 7.53% (+7.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$53.4M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$38.3M |
| 3 |
RVM
RiverVest Venture Management
St. Louis,
Missouri
|
+$26.9M |
| 4 |
A
Abingworth
London,
United Kingdom
|
+$21.9M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$12.6M |
Top Sellers
OKUR Hedge Fund Activity: Q2 2021 in Review
38 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q2 2021, worth a combined $171M.
Buyers outnumbered sellers: 38 funds opened new OKUR positions and 0 closed out — a net gain of 38 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $53.4M.
- 38 institutional investors held OnKure Therapeutics (OKUR) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $171M of OnKure Therapeutics stock for Q2 2021.
- 38 funds opened new OnKure Therapeutics positions in Q2 2021 and 0 closed out, a net change of +38 holders.
- The largest OnKure Therapeutics buyer in Q2 2021 was NEA Management Company, an estimated $53.4M added.
Based on aggregated 13F filings for Q2 2021.